CCL2 and prostate carcinoma: Taking into account the above observations, one may be less frustrated by the failure of anti-CCL2 antibody against human metastatic castration-resistant prostate cancer, a phase II study where treatment was actually well-tolerated [45]: CCL2-dependent tumors and cancer phenotypes may be defined and are yet to be discovered.